United Therapeutics Corporation Operating Lease, Expense
United Therapeutics Corporation (UTHR) reported Operating Lease, Expense of $4.80 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-02-22
- United Therapeutics Corporation operating lease, expense for the quarter ending 2019-12-31 was $1.00M.
- United Therapeutics Corporation operating lease, expense for the quarter ending 2019-09-30 was $1.20M, a 20.00% increase year-over-year.
- United Therapeutics Corporation operating lease, expense for the quarter ending 2019-06-30 was $1.30M, a 30.00% increase year-over-year.
- United Therapeutics Corporation operating lease, expense for the quarter ending 2019-03-31 was $1.40M, a 16.67% increase year-over-year.
- United Therapeutics Corporation operating lease, expense for fiscal 2022 was $4.80M, a 33.33% increase from fiscal 2021.
- United Therapeutics Corporation operating lease, expense for fiscal 2021 was $3.60M, a 2.86% increase from fiscal 2020.
- United Therapeutics Corporation operating lease, expense for fiscal 2020 was $3.50M, a 28.57% decline from fiscal 2019.
- United Therapeutics Corporation operating lease, expense for fiscal 2019 was $4.90M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $4.80M 10-K · filed 2023-02-22 | |||
| 2021-12-31 | $3.60M 10-K · filed 2023-02-22 | |||
| 2020-12-31 | $3.50M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.20M derived: sum of 2 quarters · filed 2022-02-24 | $3.50M derived: sum of 3 quarters · filed 2022-02-24 | $4.90M 10-K · filed 2022-02-24 |
| 2019-09-30 | $1.20M 10-Q · filed 2019-10-30 | $2.50M derived: sum of 2 quarters · filed 2019-10-30 | $3.90M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $1.30M 10-Q · filed 2019-07-31 | $2.70M 10-Q · filed 2019-07-31 | ||
| 2019-03-31 | $1.40M 10-Q · filed 2019-05-01 | |||
| 2018-09-30 | $1.00M 10-Q · filed 2019-10-30 | $2.00M derived: sum of 2 quarters · filed 2019-10-30 | $3.20M 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $1.00M 10-Q · filed 2019-07-31 | $2.20M 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | $1.20M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |